Mackenzie Financial Corp Purchases Shares of 41,485 Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Mackenzie Financial Corp acquired a new position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 41,485 shares of the company’s stock, valued at approximately $2,483,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Wynnefield Capital Inc. bought a new position in Apellis Pharmaceuticals in the third quarter worth approximately $380,000. General American Investors Co. Inc. bought a new position in shares of Apellis Pharmaceuticals in the 3rd quarter worth $1,712,000. Profund Advisors LLC grew its position in Apellis Pharmaceuticals by 114.5% in the 3rd quarter. Profund Advisors LLC now owns 35,153 shares of the company’s stock valued at $1,337,000 after purchasing an additional 18,766 shares during the period. Charles Schwab Investment Management Inc. increased its stake in Apellis Pharmaceuticals by 6.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 879,357 shares of the company’s stock valued at $33,451,000 after purchasing an additional 50,835 shares in the last quarter. Finally, Assenagon Asset Management S.A. raised its holdings in Apellis Pharmaceuticals by 109.6% during the fourth quarter. Assenagon Asset Management S.A. now owns 2,145,004 shares of the company’s stock worth $128,400,000 after buying an additional 1,121,497 shares during the last quarter. Institutional investors own 96.29% of the company’s stock.

Apellis Pharmaceuticals Price Performance

Shares of NASDAQ APLS opened at $47.64 on Tuesday. The firm has a market cap of $5.74 billion, a price-to-earnings ratio of -10.63 and a beta of 0.88. The stock has a fifty day simple moving average of $59.71 and a two-hundred day simple moving average of $57.31. The company has a current ratio of 3.10, a quick ratio of 2.50 and a debt-to-equity ratio of 0.48. Apellis Pharmaceuticals, Inc. has a 1-year low of $19.83 and a 1-year high of $94.75.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings results on Tuesday, February 27th. The company reported ($0.73) earnings per share for the quarter, hitting the consensus estimate of ($0.73). The company had revenue of $146.38 million during the quarter, compared to the consensus estimate of $143.34 million. Apellis Pharmaceuticals had a negative return on equity of 178.60% and a negative net margin of 133.34%. The firm’s quarterly revenue was up 545.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($1.50) EPS. Analysts anticipate that Apellis Pharmaceuticals, Inc. will post -1.33 earnings per share for the current year.

Insider Transactions at Apellis Pharmaceuticals

In related news, General Counsel David O. Watson sold 781 shares of the company’s stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $67.77, for a total transaction of $52,928.37. Following the sale, the general counsel now directly owns 103,390 shares in the company, valued at approximately $7,006,740.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other Apellis Pharmaceuticals news, insider Nur Nicholson sold 835 shares of the firm’s stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $64.14, for a total value of $53,556.90. Following the completion of the transaction, the insider now owns 67,507 shares in the company, valued at approximately $4,329,898.98. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, General Counsel David O. Watson sold 781 shares of the company’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $67.77, for a total value of $52,928.37. Following the sale, the general counsel now owns 103,390 shares in the company, valued at $7,006,740.30. The disclosure for this sale can be found here. Insiders sold 381,011 shares of company stock worth $23,463,657 over the last quarter. Corporate insiders own 7.50% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on APLS. Mizuho reiterated a “neutral” rating and set a $60.00 price objective on shares of Apellis Pharmaceuticals in a report on Wednesday, March 27th. JPMorgan Chase & Co. boosted their price objective on Apellis Pharmaceuticals from $78.00 to $79.00 and gave the stock an “overweight” rating in a report on Wednesday, March 6th. Wedbush cut their target price on Apellis Pharmaceuticals from $67.00 to $57.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 17th. The Goldman Sachs Group upped their price target on Apellis Pharmaceuticals from $65.00 to $90.00 and gave the stock a “buy” rating in a report on Tuesday, January 9th. Finally, UBS Group raised their price objective on Apellis Pharmaceuticals from $87.00 to $89.00 and gave the company a “buy” rating in a research note on Monday, March 4th. Three analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $77.93.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).